Cargando…

Adherence to omalizumab: A multicenter "real-world" study

BACKGROUND: Adherence to medications is crucial in patients with severe asthma in light of the negative clinical impact and costs of non-adherence. Adherence to omalizumab has not been well studied in real-world settings. The aim of this study was to assess adherence to omalizumab and evaluate treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campisi, Raffaele, Crimi, Claudia, Intravaia, Rossella, Strano, Simona, Noto, Alberto, Foschino, Maria Pia, Valenti, Giuseppe, Viviano, Vittorio, Pelaia, Corrado, Ricciardi, Luisa, Scichilone, Nicola, Crimi, Nunzio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016448/ https://www.ncbi.nlm.nih.gov/pubmed/32082464 http://dx.doi.org/10.1016/j.waojou.2020.100103

Ejemplares similares

Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use
por: Nolasco, Santi, et al.
Publicado: (2020)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
por: Pelaia, Corrado, et al.
Publicado: (2021)

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
por: Campisi, Raffaele, et al.
Publicado: (2023)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
por: Nolasco, Santi, et al.
Publicado: (2023)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
por: Pelaia, Corrado, et al.
Publicado: (2023)

Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
por: Campisi, Raffaele, et al.
Publicado: (2021)

Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients
por: Crimi, Claudia, et al.
Publicado: (2018)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study
por: Crimi, Claudia, et al.
Publicado: (2021)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights
por: Crimi, Claudia, et al.
Publicado: (2021)

Resumption of respiratory outpatient services in the COVID-19 era: Experience from Southern Italy
por: Crimi, Claudia, et al.
Publicado: (2020)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
por: Pelaia, Corrado, et al.
Publicado: (2021)

High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study
por: Quaranta, Vitaliano Nicola, et al.
Publicado: (2023)

Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study
por: Quaranta, Vitaliano Nicola, et al.
Publicado: (2022)

Reliability and usefulness of a rapid IgM‐IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report.
por: Spicuzza, Lucia, et al.
Publicado: (2020)

Switching Biological Therapies in Severe Asthma
por: Scioscia, Giulia, et al.
Publicado: (2023)

Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study
por: Crimi, Claudia, et al.
Publicado: (2022)

Personalized Medicine in Asthma: Current Approach and Future Perspectives
por: Nolasco, Santi, et al.
Publicado: (2023)

Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics
por: Scichilone, N., et al.
Publicado: (2016)

Early management of COPD: where are we now and where do we go from here? A Delphi consensus project
por: Di Marco, Fabiano, et al.
Publicado: (2019)

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
por: Pelaia, Corrado, et al.
Publicado: (2022)

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
por: Scioscia, Giulia, et al.
Publicado: (2020)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
por: Pelaia, Corrado, et al.
Publicado: (2018)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022)

Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Novel Biological Therapies for Severe Asthma Endotypes
por: Pelaia, Corrado, et al.
Publicado: (2022)

Remifentanil-induced postoperative hyperalgesia: current perspectives on mechanisms and therapeutic strategies
por: Santonocito, Cristina, et al.
Publicado: (2018)

Is the Power Spectrum of Electromyography Signal a Feasible Tool to Estimate Muscle Fiber Composition in Patients with COPD?
por: Casabona, Antonino, et al.
Publicado: (2021)

Update on optimal use of omalizumab in management of asthma
por: Pelaia, Girolamo, et al.
Publicado: (2011)

Impact of chronic obstructive pulmonary disease on passive viscoelastic components of the musculoarticular system
por: Valle, Maria Stella, et al.
Publicado: (2021)

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9ntotm58oc0t6jtfcg318h845s